Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yaakov Dickstein

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
BMJ Open|April 22, 2016
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolYaakov Dickstein, Leonard Leibovici, Dafna Yahav, et al.
Gerontology|October 23, 2022
External Validity of a Randomized Controlled Trial on Duration of Antibiotics for the Treatment of Gram-Negative BacteremiaAdi Turjeman, Fidi Koppel, Erica Franceschini, et al.
The Lancet. Infectious Diseases|February 20, 2018
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trialMical Paul, George L Daikos, Emanuele Durante-Mangoni, et al.
BMC Infectious Diseases|April 1, 2021
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validityVered Daitch, Mical Paul, George L Daikos, et al.
International Journal of Antimicrobial Agents|November 27, 2019
Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre studyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Infectious Diseases and Therapy|May 25, 2022
Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective StudyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2021
Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort studyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2019
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective StudyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
BMJ Open|April 22, 2016
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolYaakov Dickstein, Leonard Leibovici, Dafna Yahav, et al.
Gerontology|October 23, 2022
External Validity of a Randomized Controlled Trial on Duration of Antibiotics for the Treatment of Gram-Negative BacteremiaAdi Turjeman, Fidi Koppel, Erica Franceschini, et al.
The Lancet. Infectious Diseases|February 20, 2018
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trialMical Paul, George L Daikos, Emanuele Durante-Mangoni, et al.
BMC Infectious Diseases|April 1, 2021
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validityVered Daitch, Mical Paul, George L Daikos, et al.
International Journal of Antimicrobial Agents|November 27, 2019
Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre studyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Infectious Diseases and Therapy|May 25, 2022
Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective StudyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2021
Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort studyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2019
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective StudyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Pageof 4